The Emideltide discussion carried forward the central questions running through PCAC: what evidentiary standard applies under Section 503A, how much weight should be given to physician experience and historical use, and whether uncertainty should lead to exclusion or supervised access.
Emideltide, commonly known as delta sleep-inducing peptide or DSIP, is a nine-amino-acid peptide studied since the late 1970s for possible roles in sleep regulation, narcolepsy, and substance withdrawal. There was direct human experience involving Emideltide itself, and industry participants submitted additional studies and real-world data. FDA’s prepared analysis nevertheless focused largely on older, small studies with mixed findings that used intravenous administration rather than the proposed subcutaneous route, while later submissions had not yet been fully evaluated.
FDA found human evidence—but questioned what it established
FDA reviewed seven insomnia studies conducted between 1981 and 1992, generally involving fewer than 20 participants each. It also identified one narcolepsy case report and two open-label opioid-withdrawal studies. Some reported improvements in sleep efficiency, alertness, or withdrawal symptoms. Others found no meaningful differences across objective measures. FDA emphasized the small samples, short duration, lack of controls, and inconsistent results.
Route and dosing were also significant. The opioid-withdrawal studies used slow intravenous injections administered as often as six times per day for up to six days. FDA found no studies supporting the nominated subcutaneous route and concluded that the available evidence was insufficient to establish effectiveness for chronic insomnia, narcolepsy, or opioid withdrawal.
The safety record was viewed differently
FDA found no adverse-event reports for Emideltide in its reporting system, while cautioning that the absence of reports does not prove safety.
The intravenous insomnia studies generally described Emideltide as well tolerated. In a 1984 withdrawal study involving 107 subjects, FDA reported no significant adverse events in 95. Nine experienced symptoms such as nausea, headache, perspiration, or vertigo, and three experienced more serious events, including two cases of hypotension. FDA acknowledged that the patients’ underlying withdrawal and reported formulation problems complicated interpretation.
FDA nevertheless identified unresolved questions involving the proposed subcutaneous route, toxicity, immunogenicity, aggregation, and possible effects on opioid pathways.
Supporters emphasized roughly 45 years of human exposure, the absence of a clear hypersensitivity pattern in the literature, and retrospective pharmacy information. One speaker reported more than 100,000 doses with only one identified adverse event. Another reported more than 9,500 dispensed units without a hypotension complaint. Those reports are not controlled studies, but supporters argued that they remain relevant to a risk-based compounding decision.
As one commenter acknowledged:
“The evidence supporting Emideltide is inconclusive and at best preliminary.”
The case for inclusion was not necessarily that effectiveness had been proven. It was that longstanding exposure without a demonstrated pattern of serious harm should carry weight under a standard different from FDA approval.
FDA confirmed that PCAC was not applying the approval standard
A PCAC member asked whether the Committee was supposed to require substantial evidence of effectiveness or instead assess the substance under the four-factor 503A standard. FDA answered: “No, we are not considering evidence as substantial evidence of effectiveness.”
FDA explained that the inquiry requires a balancing of characterization, safety, available effectiveness evidence, historical use, and the uncertainty within each factor. That clarification was central. Emideltide has not completed a modern drug-development program, but PCAC was not deciding whether it qualified for marketing approval.
Characterization was possible—but FDA questioned the limits of a monograph
Industry participants presented monograph-like materials and described methods for confirming identity, potency, purity, impurities, endotoxins, sterility, particulate matter, stability, and traceability. One analytical speaker also reported potency discrepancies of up to 75% and purity failures in products obtained online. FDA did not say the molecule could not be tested. Its concern was that analytical specifications ordinarily operate alongside a defined manufacturing process and clinical information.
“A USP monograph is considered a minimal standard.”
FDA added: “It’s a real challenge to create a monograph in a vacuum.” The disagreement was therefore not over whether Emideltide can be analytically identified. It was whether characterization alone can resolve any remaining clinical uncertainties. A PCAC member noted that Committee members had reviewed proposed monographs, certificates of analysis, and supporting literature that FDA had not yet evaluated in detail.
FDA acknowledged: “We’ve certainly scanned it.”
But it would not be accurate to say the material had been “carefully reviewed.” FDA committed to considering every comment and supporting article during rulemaking, but had not completed that review before the meeting. That explanation reflects the timing of the process; however, the Committee still had to vote before FDA completed its analysis of all timely submissions. One member suggested moving future submission deadlines earlier so FDA and the Committee would be evaluating the same developed record.
A member challenged the relevance of a pharmacy prosecution
FDA referenced a criminal prosecution involving a pharmacy that had compounded Emideltide among other products as evidence of historical compounding.
One PCAC member responded: “If I was a lawyer, I would object. What in the world does that have to do with Emideltide?”
FDA explained that the prosecution identified by way of Google search was included only as evidence that the substance had been compounded. The exchange nevertheless reflected concern about creating a negative inference from conduct not tied to a demonstrated safety issue with the peptide itself.
Would listing reduce gray-market use?
Supporters argued that patients are already purchasing DSIP online without verified identity, potency, physician monitoring, or pharmacy accountability. One patient described himself as “rolling the dice” each time he bought the product online. FDA acknowledged that it had not studied whether Bulks List inclusion actually reduces gray-market demand: “I wouldn’t say that that’s something that we have ever studied.”
FDA also clarified its legal position: “Placing any substances on the list would not be restoring legal access. It would be creating legal access.”
Supporters viewed listing as harm reduction. Opponents questioned whether a regulated product would meaningfully displace less expensive online alternatives and warned that lawful listing could substantially expand overall use.
A One-Vote Divide
The Committee voted 6–7, with one abstention, against recommending Emideltide free base for the 503A Bulks List.
Members voting no emphasized the injectable route, characterization concerns, inconsistent efficacy evidence, and the lack of information needed to translate the intravenous protocols into modern prescribing. Members voting yes emphasized the defined molecule, decades of human exposure, the absence of FDA adverse-event reports, physician experience, and the role of individualized compounding where available therapies are ineffective or poorly tolerated. The National Association of Boards of Pharmacy representative abstained, maintaining the organization’s neutral position while urging FDA to work with state boards on adverse-event reporting and oversight.
One affirmative voter summarized the legal distinction: “Our duty is to apply the 503A standards, not the investigational new drug application standard.”
The member emphasized that inclusion would not approve a drug or indication; it would permit patient-specific compounding under a valid prescription. The negative recommendation was not based on a complete absence of human evidence. It reflected disagreement over what the existing evidence established and whether the gap between old intravenous studies and proposed subcutaneous use was too significant to overcome.
By a one-vote margin, the Committee concluded that it was.